Episode
Episode 178 - Kevin Finney - Chairman, President and CEO at Autobahn Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- May 22, 2026
- Duration seconds
- 2066
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-178-kevin-finney-chairman-president-and-ceo-at-autobahn-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-178-kevin-finney-chairman-president-and-ceo-at-autobahn-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, Ben sits down with Kevin Finney, President and CEO of Autobahn Therapeutics, for a conversation on biotech leadership, CNS drug development, and what it takes to build companies around difficult but high-impact areas of medicine. Kevin brings deep experience across company formation, financing, business development, and exits, including leadership roles at Abide Therapeutics, which was acquired by Lundbeck, and Zavante Therapeutics, which was later acquired by Nabriva. We discussed his career journey, the lessons learned from building and selling biotech companies, and why CNS remains one of the most challenging but important areas for therapeutic innovation. The conversation also explores Autobahn’s work in neuropsychiatry, including its focus on developing differentiated treatments for depression and related CNS disorders, as well as the strategic decisions that shape clinical development, team building, and long-term value creation. A thoughtful discussion on leadership, translational science, and the realities of advancing new medicines in neuroscience.